Two drugmakers have petitioned the FDA to change how market exclusivity is granted for combination drugs. The agency grants five years' exclusivity only if all active compounds in a combination drug are new. The drugmakers are asking the FDA to consider that protection for combinations that include any previously unapproved active ingredients.